NASDAQ:OCX OncoCyte (OCX) Stock Forecast, Price & News $0.22 -0.01 (-4.36%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.21▼$0.2350-Day Range$0.21▼$0.2752-Week Range$0.20▼$1.35Volume369,127 shsAverage Volume233,045 shsMarket Capitalization$36.19 millionP/E RatioN/ADividend YieldN/APrice Target$1.11 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media OncoCyte MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside406.6% Upside$1.11 Price TargetShort InterestHealthy0.70% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 4 Articles This WeekInsider TradingAcquiring Shares$8.25 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.28) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector209th out of 983 stocksDiagnostic Substances Industry6th out of 15 stocks 3.2 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.11, OncoCyte has a forecasted upside of 406.6% from its current price of $0.22.Amount of Analyst CoverageOncoCyte has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.70% of the outstanding shares of OncoCyte have been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OncoCyte has recently decreased by 2.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 1.8 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OncoCyte this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,247,191.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.65% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions81.20% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for OncoCyte are expected to grow in the coming year, from ($0.28) to ($0.27) per share.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoCyte (NASDAQ:OCX) StockOncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.Read More Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Stock News HeadlinesJune 3, 2023 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comJune 1, 2023 | finance.yahoo.comOncocyte Corporation to Present at the LD Micro Invitational XIIIJune 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 28, 2023 | americanbankingnews.comOncoCyte (NYSE:OCX) Research Coverage Started at StockNews.comMay 28, 2023 | americanbankingnews.comOncoCyte (NYSE:OCX) Now Covered by Analysts at StockNews.comMay 11, 2023 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comOncocyte Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comOncoCyte Q1 2023 Earnings PreviewJune 4, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 9, 2023 | americanbankingnews.comOncoCyte (OCX) to Release Earnings on ThursdayMay 8, 2023 | americanbankingnews.comOncoCyte (NYSE:OCX) Receives New Coverage from Analysts at StockNews.comMay 2, 2023 | americanbankingnews.comOncoCyte (NYSE:OCX) Coverage Initiated at StockNews.comApril 27, 2023 | finance.yahoo.comOncocyte To Announce First Quarter 2023 Financial ResultsApril 27, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on OncoCyte (NYSE:OCX)April 19, 2023 | americanbankingnews.comOncoCyte (NYSE:OCX) Now Covered by StockNews.comApril 18, 2023 | finance.yahoo.comOncocyte Presents New Data at AACRApril 13, 2023 | msn.comOncocyte's Announces Another Round Of Layoffs Leaving 20% Of Staff ImpactedApril 12, 2023 | markets.businessinsider.comOncocyte Reduces Workforce By 20%April 12, 2023 | finance.yahoo.comOncocyte Announces Reduction in ForceApril 12, 2023 | 247wallst.comBroadwood Partners Now Owns 33.3% of OncoCyteApril 10, 2023 | finance.yahoo.comOncoCyte Corporation (NASDAQ:OCX) Q4 2022 Earnings Call TranscriptApril 9, 2023 | nasdaq.comBroadwood Partners Now Owns 33.30% of OncoCyte (OCX)April 8, 2023 | americanbankingnews.comOncoCyte Co. (NASDAQ:OCX) Major Shareholder Pura Vida Investments, Llc Buys 663,000 Shares of StockApril 8, 2023 | americanbankingnews.comOncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Acquires 26,827,638 SharesApril 7, 2023 | finance.yahoo.comOncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal CancerApril 6, 2023 | americanbankingnews.comOncoCyte (NASDAQ:OCX) PT Lowered to $0.45April 3, 2023 | finance.yahoo.comOncocyte Pricing of $13.86 Million Public Offering of Common StockSee More Headlines OCX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Company Calendar Last Earnings11/09/2021Today6/03/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$1.11 High Stock Price Forecast$3.00 Low Stock Price Forecast$0.45 Forecasted Upside/Downside+406.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,900,000.00 Net Margins-787.97% Pretax Margin-1,056.00% Return on Equity-34.08% Return on Assets-15.49% Debt Debt-to-Equity RatioN/A Current Ratio1.66 Quick Ratio1.66 Sales & Book Value Annual Sales$960,000.00 Price / Sales37.70 Cash Flow$0.04 per share Price / Cash Flow5.09 Book Value$0.32 per share Price / Book0.69Miscellaneous Outstanding Shares164,820,000Free Float111,347,000Market Cap$36.19 million OptionableOptionable Beta1.58 Key ExecutivesJoshua RiggsPresident, Chief Executive Officer & DirectorAnish JohnChief Financial Officer & Senior Vice PresidentEkkehard SchützChief Science OfficerYuh-Min ChiangSenior Vice President-Research & DevelopmentPadma SundarChief Commercial OfficerKey CompetitorsBiomericaNASDAQ:BMRAAspira Women's HealthNASDAQ:AWHTrinity BiotechNASDAQ:TRIBCardio DiagnosticsNASDAQ:CDIOImmuCellNASDAQ:ICCCView All CompetitorsInsiders & InstitutionsDefender Capital LLC.Bought 90,500 shares on 4/27/2023Ownership: 1.981%Pura Vida Investments, LlcBought 663,000 shares on 4/5/2023Total: $198,900.00 ($0.30/share)Broadwood Partners, L.P.Bought 26,827,638 shares on 4/3/2023Total: $8.05 M ($0.30/share)Alfred D KingsleyBought 25,000 shares on 12/22/2022Total: $7,000.00 ($0.28/share)Andrew J LastBought 20,000 shares on 8/17/2022Total: $17,400.00 ($0.87/share)View All Insider TransactionsView All Institutional Transactions OCX Stock - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price forecast for 2023? 3 analysts have issued 12 month price targets for OncoCyte's stock. Their OCX share price forecasts range from $0.45 to $3.00. On average, they anticipate the company's share price to reach $1.11 in the next year. This suggests a possible upside of 406.6% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2023? OncoCyte's stock was trading at $0.3209 on January 1st, 2023. Since then, OCX stock has decreased by 31.6% and is now trading at $0.2196. View the best growth stocks for 2023 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The company earned $0.98 million during the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 34.08%. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). What is OncoCyte's stock symbol? OncoCyte trades on the NASDAQ under the ticker symbol "OCX." Who are OncoCyte's major shareholders? OncoCyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.98%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $0.22. How much money does OncoCyte make? OncoCyte (NASDAQ:OCX) has a market capitalization of $36.19 million and generates $960,000.00 in revenue each year. How can I contact OncoCyte? OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389. This page (NASDAQ:OCX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.